Content of review 1, reviewed on November 08, 2023

  1. The authors also included data from type 1 diabetic patients in the study. SGLT-2i has no such indication. The authors should clarify this issue.

  2. Patients over the age of 18 were included in the study. If the data of type 2 diabetic patients are to be given, the chance of having type 2 diabetes at this age is very small. The authors should clarify.

  3. 10% of patients discontinued SGLT2i treatment. Can the reasons for these be given?

Additionally, SGLT2i treatment was permanent in 55% of patients. Why was SGLT2i treatment discontinued in other patients?

  1. The authors revealed that the frequency of SGLT2i use has increased only in France. What was the result of this? Has diabetes regulation increased? Have diabetic complications decreased?

  2. The authors gave data from patients with heart failure and nephropathy. Are these patients without diabetes? What is the treatment result?

  3. Internists (internal medicine) appear to prescribe very little SGLT2i. What is the reason for this?

Source

    © 2023 the Reviewer.

Content of review 2, reviewed on January 12, 2024

I have no further comments

Source

    © 2024 the Reviewer.

References

    Sibylle, d. G., Elodie, P., Antoine, P., Guillaume, G., Julien, B., Jean-Luc, F. 2024. Use of sodium-glucose cotransporter-2 inhibitors in France: Analysis of French nationwide health insurance database. Diabetes, Obesity and Metabolism.